Very good. The company is a biomedical high-tech enterprise integrating R&D, production and sales of in vitro diagnostic reagents, POCT instruments and biological raw materials. It focuses on the R&D, production and sales of POCT reagents and instruments, and also focuses on the development and product technology of biological raw material platforms. The reserve has now formed an integrated industrial chain layout from upstream core biological raw materials to diagnostic reagents and instruments. It is one of the few Chinese companies in the country that can compete with multinational in vitro diagnostic giants in the international market.
The total investment of Anxu Biotech Fuyang project is 5.08 yuan. It is a project constructed by Anxu Biotech using super-raised funds.